Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-2926
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Immune Checkpoint Inhibitor-Induced Fanconi Syndrome

Cureus
2020English

Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020

Kidney360
2020English

With Phases: How Two Wrongs Can Sometimes Make a Right

Acta Crystallographica Section D Biological Crystallography
2010English

In Reply — Immune Checkpoint Inhibitor–Induced Type 1 Diabetes: An Underestimated Risk

Mayo Clinic Proceedings
Medicine
2020English

Development of PARP and Immune-Checkpoint Inhibitor Combinations

Cancer Research
Cancer ResearchOncology
2018English

Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy

Case Reports in Oncological Medicine
Oncology
2017English

Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review

Internal Medicine
Internal MedicineMedicine
2019English

Management of Immune Checkpoint Inhibitor‐related Dermatologic Adverse Events

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Reporting of Immune Checkpoint Inhibitor-Associated Myocarditis – Authors' Reply

The Lancet
Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy